| Year |
Citation |
Score |
| 2017 |
Shams S, Amlani S, Buske C, Chatterjee D, Gerlai R. Developmental social isolation affects adult behavior, social interaction, and dopamine metabolite levels in zebrafish. Developmental Psychobiology. PMID 29091281 DOI: 10.1002/Dev.21581 |
0.62 |
|
| 2015 |
Buske C. Zebrafish social behavior testing in developmental brain disorders Organism Models of Autism Spectrum Disorders. 303-316. DOI: 10.1007/978-1-4939-2250-5_12 |
0.39 |
|
| 2014 |
Buske C, Gerlai R. Diving deeper into Zebrafish development of social behavior: analyzing high resolution data. Journal of Neuroscience Methods. 234: 66-72. PMID 24970579 DOI: 10.1016/J.Jneumeth.2014.06.019 |
0.574 |
|
| 2013 |
Mahabir S, Chatterjee D, Buske C, Gerlai R. Maturation of shoaling in two zebrafish strains: a behavioral and neurochemical analysis. Behavioural Brain Research. 247: 1-8. PMID 23518435 DOI: 10.1016/J.Bbr.2013.03.013 |
0.633 |
|
| 2013 |
Saif M, Chatterjee D, Buske C, Gerlai R. Sight of conspecific images induces changes in neurochemistry in zebrafish. Behavioural Brain Research. 243: 294-9. PMID 23357085 DOI: 10.1016/J.Bbr.2013.01.020 |
0.511 |
|
| 2012 |
Buske C, Gerlai R. Maturation of shoaling behavior is accompanied by changes in the dopaminergic and serotoninergic systems in zebrafish. Developmental Psychobiology. 54: 28-35. PMID 21656763 DOI: 10.1002/Dev.20571 |
0.631 |
|
| 2011 |
Buske C, Gerlai R. Early embryonic ethanol exposure impairs shoaling and the dopaminergic and serotoninergic systems in adult zebrafish. Neurotoxicology and Teratology. 33: 698-707. PMID 21658445 DOI: 10.1016/J.Ntt.2011.05.009 |
0.594 |
|
| 2011 |
Buske C, Gerlai R. Shoaling develops with age in Zebrafish (Danio rerio). Progress in Neuro-Psychopharmacology & Biological Psychiatry. 35: 1409-15. PMID 20837077 DOI: 10.1016/J.Pnpbp.2010.09.003 |
0.631 |
|
| 2011 |
Echevarria DJ, Buske C, Toms CN, Jouandot DJ. A novel test battery to assess drug-induced changes in zebrafish social behavior Neuromethods. 51: 109-124. DOI: 10.1007/978-1-60761-953-6_9 |
0.329 |
|
| 2006 |
Sison M, Cawker J, Buske C, Gerlai R. Fishing for genes influencing vertebrate behavior: zebrafish making headway. Lab Animal. 35: 33-9. PMID 16645614 DOI: 10.1038/Laban0506-33 |
0.582 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2001 |
Buske C, Feuring-Buske M, Antonchuk J, Rosten P, Hogge DE, Eaves CJ, Humphries RK. Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo Blood. 97: 2286-2292. PMID 11290589 DOI: 10.1182/Blood.V97.8.2286 |
0.112 |
|
| 2002 |
Buske C, Feuring-Buske M, Abramovich C, Spiekermann K, Eaves CJ, Coulombel L, Sauvageau G, Hogge DE, Humphries RK. Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells. Blood. 100: 862-8. PMID 12130496 DOI: 10.1182/Blood-2002-01-0220 |
0.112 |
|
| 2006 |
Feuring-Buske M, Hartmann EM, Ott G, Reuter H, Buske C, Rosenwald A. [DNA-chips in the diagnosis of hematological malignancies]. Der Internist. 47: 39-46. PMID 16247632 DOI: 10.1007/s00108-005-1526-2 |
0.11 |
|
| 2016 |
Daria D, Kirsten N, Muranyi A, Mulaw M, Ihme S, Kechter A, Bullinger L, Döhner K, Döhner H, Feuring-Buske M, Buske C. GPR56 contributes to the development of acute myeloid leukemia in mice. Leukemia. PMID 27063597 DOI: 10.1038/leu.2016.76 |
0.109 |
|
| 2006 |
Kuchenbauer F, Schnittger S, Look T, Gilliland G, Tenen D, Haferlach T, Hiddemann W, Buske C, Schoch C. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. British Journal of Haematology. 134: 616-9. PMID 16938118 DOI: 10.1111/J.1365-2141.2006.06229.X |
0.108 |
|
| 2005 |
Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM, Spiekermann K, Humphries RK, Schnittger S, Kern W, Hiddemann W, Quintanilla-Martinez L, Bohlander SK, Feuring-Buske M, Buske C. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. The Journal of Clinical Investigation. 115: 2159-68. PMID 16025155 DOI: 10.1172/JCI24225 |
0.107 |
|
| 2003 |
Pineault N, Buske C, Feuring-Buske M, Abramovich C, Rosten P, Hogge DE, Aplan PD, Humphries RK. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood. 101: 4529-38. PMID 12543865 DOI: 10.1182/Blood-2002-08-2484 |
0.105 |
|
| 2015 |
Buske C, Kirchhoff F, Münch J. EPI-X4, a novel endogenous antagonist of CXCR4. Oncotarget. PMID 26459389 DOI: 10.18632/Oncotarget.6037 |
0.105 |
|
| 2008 |
Ahmed F, Arseni N, Glimm H, Hiddemann W, Buske C, Feuring-Buske M. Constitutive expression of the ATP-binding cassette transporter ABCG2 enhances the growth potential of early human hematopoietic progenitors. Stem Cells (Dayton, Ohio). 26: 810-8. PMID 18055445 DOI: 10.1634/stemcells.2007-0527 |
0.101 |
|
| 2009 |
Thoene S, Rawat VP, Heilmeier B, Hoster E, Metzeler KH, Herold T, Hiddemann W, Gökbuget N, Hoelzer D, Bohlander SK, Feuring-Buske M, Buske C. The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia. Leukemia. 23: 649-55. PMID 19158837 DOI: 10.1038/leu.2008.355 |
0.099 |
|
| 2014 |
Stadler CR, Vegi N, Mulaw MA, Edmaier KE, Rawat VP, Dolnik A, Bullinger L, Heilmeier B, Quintanilla-Fend L, Spiekermann K, Hiddemann W, Döhner K, Döhner H, Feuring-Buske M, Buske C. The leukemogenicity of Hoxa9 depends on alternative splicing. Leukemia. 28: 1838-43. PMID 24535405 DOI: 10.1038/leu.2014.74 |
0.099 |
|
| 2011 |
Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J, Canty AJ, Danska JS, Bohlander SK, Buske C, Minden MD, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Medicine. 17: 1086-93. PMID 21873988 DOI: 10.1038/Nm.2415 |
0.093 |
|
| 2008 |
Petropoulos K, Arseni N, Schessl C, Stadler CR, Rawat VP, Deshpande AJ, Heilmeier B, Hiddemann W, Quintanilla-Martinez L, Bohlander SK, Feuring-Buske M, Buske C. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. The Journal of Experimental Medicine. 205: 515-22. PMID 18316418 DOI: 10.1084/jem.20071875 |
0.088 |
|
| 2010 |
Rawat VP, Arseni N, Ahmed F, Mulaw MA, Thoene S, Heilmeier B, Sadlon T, D'Andrea RJ, Hiddemann W, Bohlander SK, Buske C, Feuring-Buske M. The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 107: 16946-51. PMID 20833819 DOI: 10.1073/pnas.1001878107 |
0.088 |
|
| 2009 |
Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B, Mellert G, Vempati S, Duyster J, Buske C, Bohlander SK, Humphries KR, Hiddemann W, Spiekermann K. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2238-47. PMID 19276253 DOI: 10.1158/1078-0432.CCR-08-1325 |
0.085 |
|
| 2012 |
Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Rosée P, Kirchner H, Kiewe P, Keller U, Buske C, et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Annals of Hematology. 91: 1765-72. PMID 22926531 DOI: 10.1007/s00277-012-1534-y |
0.084 |
|
| 2009 |
Deshpande AJ, Ahmed F, Buske C. Identification of murine and human acute myeloid leukemia stem cells. Methods in Molecular Biology (Clifton, N.J.). 568: 21-35. PMID 19582419 DOI: 10.1007/978-1-59745-280-9_3 |
0.083 |
|
| 2014 |
Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Sauerland MC, et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1586-94. PMID 24711548 DOI: 10.1200/JCO.2013.52.3480 |
0.082 |
|
| 2011 |
Mohr F, Döhner K, Buske C, Rawat VP. TET genes: new players in DNA demethylation and important determinants for stemness. Experimental Hematology. 39: 272-81. PMID 21168469 DOI: 10.1016/j.exphem.2010.12.004 |
0.08 |
|
| 2012 |
Rawat VP, Humphries RK, Buske C. Beyond Hox: the role of ParaHox genes in normal and malignant hematopoiesis. Blood. 120: 519-27. PMID 22547580 DOI: 10.1182/blood-2012-02-385898 |
0.078 |
|
| 2016 |
Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, et al. Treatment recommendations for Waldenström macroglobulinemia from the Eighth International Workshop on WM. Blood. PMID 27432877 DOI: 10.1182/blood-2016-04-711234 |
0.078 |
|
| 2016 |
Schmid F, Schmid M, Müssel C, Sträng JE, Buske C, Bullinger L, Kraus JM, Kestler HA. GiANT: Gene set uncertainty in enrichment analysis. Bioinformatics (Oxford, England). PMID 26833345 DOI: 10.1093/bioinformatics/btw030 |
0.077 |
|
| 2009 |
Rao AV, Valk PJ, Metzeler KH, Acharya CR, Tuchman SA, Stevenson MM, Rizzieri DA, Delwel R, Buske C, Bohlander SK, Potti A, Löwenberg B. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5580-6. PMID 19858393 DOI: 10.1200/JCO.2009.22.2547 |
0.076 |
|
| 2012 |
Bamezai S, Rawat VP, Buske C. Concise review: The Piwi-piRNA axis: pivotal beyond transposon silencing. Stem Cells (Dayton, Ohio). 30: 2603-11. PMID 22996918 DOI: 10.1002/stem.1237 |
0.075 |
|
| 2015 |
Bartoli C, Blanchard A, Buske C, Collod-Béroud G, Fasano L, Scajola C, Roubertoux PL. Selecting the right species: Practical information on organism models Organism Models of Autism Spectrum Disorders. 67-97. DOI: 10.1007/978-1-4939-2250-5_3 |
0.074 |
|
| 2006 |
Deshpande AJ, Cusan M, Rawat VP, Reuter H, Krause A, Pott C, Quintanilla-Martinez L, Kakadia P, Kuchenbauer F, Ahmed F, Delabesse E, Hahn M, Lichter P, Kneba M, Hiddemann W, ... ... Buske C, et al. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell. 10: 363-74. PMID 17097559 DOI: 10.1016/j.ccr.2006.08.023 |
0.074 |
|
| 2012 |
Metzeler KH, Heilmeier B, Edmaier KE, Rawat VP, Dufour A, Döhner K, Feuring-Buske M, Braess J, Spiekermann K, Büchner T, Sauerland MC, Döhner H, Hiddemann W, Bohlander SK, Schlenk RF, ... ... Buske C, et al. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood. 120: 2118-26. PMID 22815426 DOI: 10.1182/blood-2012-02-411827 |
0.072 |
|
| 2009 |
Lin YH, Kakadia PM, Chen Y, Li YQ, Deshpande AJ, Buske C, Zhang KL, Zhang Y, Xu GL, Bohlander SK. Global reduction of the epigenetic H3K79 methylation mark and increased chromosomal instability in CALM-AF10-positive leukemias. Blood. 114: 651-8. PMID 19443658 DOI: 10.1182/Blood-2009-03-209395 |
0.071 |
|
| 2008 |
Rawat VP, Thoene S, Naidu VM, Arseni N, Heilmeier B, Metzeler K, Petropoulos K, Deshpande A, Quintanilla-Martinez L, Bohlander SK, Spiekermann K, Hiddemann W, Feuring-Buske M, Buske C. Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia. Blood. 111: 309-19. PMID 17855634 DOI: 10.1182/blood-2007-04-085407 |
0.071 |
|
| 2015 |
Hess G, Keller U, Scholz CW, Witzens-Harig M, Atta J, Buske C, Kirschey S, Ruckes C, Medler C, van Oordt C, Klapper W, Theobald M, Dreyling M. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. Leukemia. PMID 25765545 DOI: 10.1038/leu.2015.60 |
0.07 |
|
| 2016 |
Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27056999 DOI: 10.1093/annonc/mdw025 |
0.068 |
|
| 2013 |
Fey MF, Buske C. Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: vi138-43. PMID 23970018 DOI: 10.1093/annonc/mdt320 |
0.068 |
|
| 2009 |
Heilmeier B, Spiekermann K, Bohlander S, Buske C, Feuring-Buske M, Schneider S, Hiddemann W, Braess J. [Modern leukemia diagnosis in adults]. Deutsche Medizinische Wochenschrift (1946). 134: 1222-6. PMID 19472094 DOI: 10.1055/s-0029-1222598 |
0.067 |
|
| 2013 |
Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 27: 813-22. PMID 23138183 DOI: 10.1038/leu.2012.327 |
0.067 |
|
| 2010 |
Schöler N, Langer C, Döhner H, Buske C, Kuchenbauer F. Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Experimental Hematology. 38: 1126-30. PMID 20977925 DOI: 10.1016/j.exphem.2010.10.004 |
0.065 |
|
| 2003 |
Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, Schnittger S, Kelly LM, Gilliland DG, Hiddemann W. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood. 101: 1494-504. PMID 12406902 DOI: 10.1182/blood-2002-04-1045 |
0.065 |
|
| 2015 |
Schneider V, Zhang L, Rojewski M, Fekete N, Schrezenmeier H, Erle A, Bullinger L, Hofmann S, Götz M, Döhner K, Ihme S, Döhner H, Buske C, Feuring-Buske M, Greiner J. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. International Journal of Cancer. Journal International Du Cancer. PMID 25912930 DOI: 10.1002/ijc.29583 |
0.065 |
|
| 2013 |
Diffner E, Beck D, Gudgin E, Thoms JA, Knezevic K, Pridans C, Foster S, Goode D, Lim WK, Boelen L, Metzeler KH, Micklem G, Bohlander SK, Buske C, Burnett A, et al. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia. Blood. 121: 2289-300. PMID 23327922 DOI: 10.1182/Blood-2012-07-446120 |
0.064 |
|
| 2009 |
Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig WD, Schimke J, Schmitz S, Kneba M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 23: 153-61. PMID 18818699 DOI: 10.1038/leu.2008.261 |
0.063 |
|
| 2005 |
Arseni N, Ahmed F, Hiddemann W, Buske C, Feuring-Buske M. Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells. Haematologica. 90: 1577-8. PMID 16266907 |
0.062 |
|
| 2008 |
Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Büchner T, ... ... Buske C, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 112: 4193-201. PMID 18716133 DOI: 10.1182/blood-2008-02-134411 |
0.061 |
|
| 2007 |
Deshpande AJ, Buske C. Knocking the Wnt out of the sails of leukemia stem cell development. Cell Stem Cell. 1: 597-8. PMID 18371398 DOI: 10.1016/j.stem.2007.11.006 |
0.06 |
|
| 1998 |
Hannig H, Buske C, Mätz-Rensing K, Hunsmann G, Hiddemann W, Bodemer W. Elevated serum level of soluble CD23 precedes development of B-non- Hodgkin's lymphoma in SIV-infected rhesus monkeys International Journal of Cancer. 77: 734-740. PMID 9688307 DOI: 10.1002/(SICI)1097-0215(19980831)77:5<734::AID-IJC12>3.0.CO;2-1 |
0.058 |
|
| 2007 |
Metzeler KH, Braess J, Spiekermann K, Bohlander SK, Hiddemann W, Buske C, Feuring-Buske M. [Fortuitous finding: thrombocytopenia and thrombocytosis]. Mmw Fortschritte Der Medizin. 149: 34-5, 37. PMID 17668774 |
0.058 |
|
| 2001 |
Buske C, Feuring-Buske M, Hogge DE, Eaves CJ, Humphries RK. Constitutive expression of the homeobox transcription factor HOXB4 amplifies human primitive hematopoietic progenitor cells in vitro and in vivo European Journal of Cancer. 37: S87. |
0.058 |
|
| 2016 |
Grunenberg A, Buske C. [New developments in Waldenström's macroglobulinemia]. Deutsche Medizinische Wochenschrift (1946). 141: 170-172. PMID 26841176 DOI: 10.1055/s-0041-107960 |
0.058 |
|
| 1994 |
Buske C, Hiddemann W, Wormann B. Proliferation of human leukemic pre-B cells induced by human bone marrow stromal cells and murine fibroblasts Cell Biology International. 18: 1049-1058. PMID 7894389 DOI: 10.1006/cbir.1994.1028 |
0.057 |
|
| 2007 |
Schneider F, Bohlander SK, Schneider S, Papadaki C, Kakadyia P, Dufour A, Vempati S, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Wandt H, Hiddemann W, Spiekermann K. AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia. Leukemia. 21: 2199-201. PMID 17625612 DOI: 10.1038/sj.leu.2404830 |
0.057 |
|
| 2002 |
Feuring-Buske M, Hiddemann W, Buske C. [Pathogenesis and biology of leukemias]. Der Internist. 43: 1179-89. PMID 12524900 DOI: 10.1007/s00108-002-0701-y |
0.056 |
|
| 2016 |
Vegi NM, Klappacher J, Oswald F, Mulaw MA, Mandoli A, Thiel VN, Bamezai S, Feder K, Martens JH, Rawat VP, Mandal T, Quintanilla-Martinez L, Spiekermann K, Hiddemann W, Döhner K, ... ... Buske C, et al. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML. Cell Reports. PMID 27346355 DOI: 10.1016/j.celrep.2016.05.094 |
0.055 |
|
| 1999 |
Feuring-Buske M, Haase D, Buske C, Hiddemann W, Wörmann B. Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission Leukemia. 13: 386-392. PMID 10086729 |
0.052 |
|
| 2016 |
Grunenberg A, Buske C. [Waldenström's macroglobulinemia : Current developments in diagnostics and therapy]. Der Internist. PMID 26830425 DOI: 10.1007/s00108-015-0005-7 |
0.052 |
|
| 2004 |
Rawat VP, Cusan M, Deshpande A, Hiddemann W, Quintanilla-Martinez L, Humphries RK, Bohlander SK, Feuring-Buske M, Buske C. Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 101: 817-22. PMID 14718672 DOI: 10.1073/pnas.0305555101 |
0.051 |
|
| 2000 |
Feuring-Buske M, Buske C, Unterhalt M, Hiddemann W. Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma Annals of Hematology. 79: 167-174. PMID 10834503 |
0.051 |
|
| 1999 |
Buske C, Feuring-Buske M, Unterhalt M, Hiddemann W. New advances in the treatment of non-Hodgkin lymphoma with monoclonal antibodies | Neue entwicklungen in der therapie von non-Hodgkin lymphomen mit monoklonalen antikorpern Deutsche Medizinische Wochenschrift. 124: 842-847. PMID 10432945 |
0.051 |
|
| 2004 |
Buske C, Dreyling H, Unterhalt M, Hiddemann W. Novel treatment strategies in follicular lymphoma. Annals of Hematology. 83: S72. PMID 15124680 DOI: 10.1007/s00277-004-0850-2 |
0.051 |
|
| 2013 |
Wu Y, Ihme S, Feuring-Buske M, Kuan SL, Eisele K, Lamla M, Wang Y, Buske C, Weil T. A core-shell albumin copolymer nanotransporter for high capacity loading and two-step release of doxorubicin with enhanced anti-leukemia activity. Advanced Healthcare Materials. 2: 884-94. PMID 23225538 DOI: 10.1002/Adhm.201200296 |
0.051 |
|
| 2011 |
Deshpande AJ, Rouhi A, Lin Y, Stadler C, Greif PA, Arseni N, Opatz S, Quintanilla-Fend L, Holzmann K, Hiddemann W, Döhner K, Döhner H, Xu G, Armstrong SA, Bohlander SK, ... Buske C, et al. The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia. 25: 1718-27. PMID 21681188 DOI: 10.1038/Leu.2011.153 |
0.05 |
|
| 2006 |
Buske C, Hiddemann W. Rituximab maintenance therapy in indolent NHL: a clinical review. Leukemia Research. 30: S11-5. PMID 16750673 DOI: 10.1016/S0145-2126(06)80003-2 |
0.05 |
|
| 2009 |
Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland MC, Heinecke A, Berdel WE, Büchner T, Wörmann B, Mansmann U, Braess J, Spiekermann K, Hiddemann W, Buske C, Bohlander SK. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5031-8. PMID 19752345 DOI: 10.1200/JCO.2008.20.5328 |
0.05 |
|
| 2008 |
Vempati S, Reindl C, Wolf U, Kern R, Petropoulos K, Naidu VM, Buske C, Hiddemann W, Kohl TM, Spiekermann K. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4437-45. PMID 18628457 DOI: 10.1158/1078-0432.CCR-07-1873 |
0.05 |
|
| 2014 |
Edmaier KE, Stahnke K, Vegi N, Mulaw M, Ihme S, Scheffold A, Rudolph KL, Buske C. Expression of the lymphoid enhancer factor 1 is required for normal hematopoietic stem and progenitor cell function. Leukemia. 28: 227-30. PMID 23942465 DOI: 10.1038/leu.2013.238 |
0.049 |
|
| 2012 |
Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Kakadia PM, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Heinecke A, Sauerland MC, et al. The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. Blood. 119: 4383-6. PMID 22374696 DOI: 10.1182/blood-2010-12-327072 |
0.049 |
|
| 2015 |
Gentner B, Pochert N, Rouhi A, Boccalatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-Hösle M, Ruschmann J, Muranyi A, Leierseder S, Argiropoulos B, Starczynowski DT, Karsan A, ... ... Buske C, et al. MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Experimental Hematology. 43: 858-868.e7. PMID 26163797 DOI: 10.1016/J.Exphem.2015.05.018 |
0.047 |
|
| 2014 |
Fenaux P, Haase D, Sanz GF, Santini V, Buske C. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: iii57-69. PMID 25185242 DOI: 10.1093/annonc/mdu180 |
0.047 |
|
| 1971 |
Krell L, Elste G, Buske C, Mohr J. Diagnosis of gonorrhea with laboratory methods, including the specific immunofluorescence test (FAT). 3. Specific demonstration of Neisseria gonorrhoeae by immunofluorescence | Die Diagnostik der Donorrhoe mit labortechnischen Methoden, einschliesslich des spezifischen Immunofluoreszentestes (FAT). 3. Der spezifische Nachweis von Neisseria gonorrhoeae durch Immunofluorezenz Deutsche Gesundheitswesen. 26: 1804-1807. PMID 4111031 |
0.047 |
|
| 2015 |
Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: v100-7. PMID 26269205 DOI: 10.1093/annonc/mdv200 |
0.047 |
|
| 2006 |
Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 108: 1504-8. PMID 16690968 DOI: 10.1182/blood-2006-01-013367 |
0.047 |
|
| 2005 |
Dreyling M, Buske C, Hiddemann W. Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 16: ii99-104. PMID 15958485 DOI: 10.1093/annonc/mdi724 |
0.046 |
|
| 2015 |
Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kröger N, Thiele J, Buske C. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: v85-99. PMID 26242182 DOI: 10.1093/annonc/mdv203 |
0.044 |
|
| 2015 |
Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: v78-84. PMID 26314781 DOI: 10.1093/annonc/mdv303 |
0.044 |
|
| 2011 |
Rouhi A, Buske C. Stem cells and beyond: report on the 40th Annual Scientific Meeting of the International Society of Experimental Hematology. Expert Review of Hematology. 4: 591-2. PMID 22077522 DOI: 10.1586/ehm.11.65 |
0.043 |
|
| 2020 |
Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: 860-862. PMID 30520968 DOI: 10.1093/annonc/mdy466 |
0.043 |
|
| 2013 |
Buske C, Leblond V, Dimopoulos M, Kimby E, Jäger U, Dreyling M. Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: vi155-9. PMID 24078658 DOI: 10.1093/annonc/mdt298 |
0.042 |
|
| 2011 |
Herold T, Jurinovic V, Metzeler KH, Boulesteix AL, Bergmann M, Seiler T, Mulaw M, Thoene S, Dufour A, Pasalic Z, Schmidberger M, Schmidt M, Schneider S, Kakadia PM, Feuring-Buske M, ... ... Buske C, et al. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia. 25: 1639-45. PMID 21625232 DOI: 10.1038/leu.2011.125 |
0.042 |
|
| 2009 |
Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Fritsch S, Heinecke A, Sauerland MC, et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood. 113: 5250-3. PMID 19279329 DOI: 10.1182/blood-2008-09-172668 |
0.041 |
|
| 2005 |
Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R, Nickenig C, Unterhalt M. Treatment strategies in follicular lymphomas: current status and future perspectives. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6394-9. PMID 16155025 DOI: 10.1200/JCO.2005.07.019 |
0.04 |
|
| 2013 |
Grasedieck S, Sorrentino A, Langer C, Buske C, Döhner H, Mertens D, Kuchenbauer F. Circulating microRNAs in hematological diseases: principles, challenges, and perspectives. Blood. 121: 4977-84. PMID 23550041 DOI: 10.1182/blood-2013-01-480079 |
0.039 |
|
| 1999 |
Buske C, Feuring-Buske M, Unterhalt M, Hiddemann W. Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: Emerging concepts of a tumour-targeted strategy European Journal of Cancer. 35: 549-557. PMID 10492626 DOI: 10.1016/S0959-8049(98)00420-1 |
0.039 |
|
| 2009 |
Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Ludwig WD, Serve H, Reichle A, Peceny R, Oruzio D, Schmid C, Schiel X, Hentrich M, Sauerland C, Unterhalt M, ... ... Buske C, et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood. 113: 3903-10. PMID 19131552 DOI: 10.1182/blood-2008-07-162842 |
0.038 |
|
| 2013 |
Herold T, Mulaw MA, Jurinovic V, Seiler T, Metzeler KH, Dufour A, Schneider S, Kakadia PM, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Dreyling M, Bohlander SK. High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature. Leukemia & Lymphoma. 54: 1652-7. PMID 23189934 DOI: 10.3109/10428194.2012.753445 |
0.036 |
|
| 2008 |
Buske C, Gisselbrecht C, Gribben J, Letai T, McLaughlin P, Wilson W. Refining the treatment of follicular lymphoma. Leukemia & Lymphoma. 49: 18-26. PMID 18821429 DOI: 10.1080/10428190802311409 |
0.036 |
|
| 2001 |
Blaschke S, Hannig H, Buske C, Kaup FJ, Hunsmann G, Bodemer W. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults Journal of Medical Virology. 65: 6-13. PMID 11505437 DOI: 10.1002/jmv.1094 |
0.036 |
|
| 2007 |
Deshpande AJ, Buske C. Lymphoid progenitors as candidate cancer stem cells in AML: new perspectives. Cell Cycle (Georgetown, Tex.). 6: 543-5. PMID 17329976 |
0.035 |
|
| 1998 |
Wormann B, Buske C, Hiddemann W. Systemic therapy of low malignant non-Hodgkin's lymphomas | Systemische Therapie bei niedrigmalignen Non-Hodgkin-Lymphomen Praxis. 87: 806-811. PMID 9654987 |
0.035 |
|
| 2008 |
Hummel M, Metzeler KH, Buske C, Bohlander SK, Mansmann U. Association between a prognostic gene signature and functional gene sets. Bioinformatics and Biology Insights. 2: 329-41. PMID 19812786 |
0.035 |
|
| 2002 |
Buske C, Hiddemann W. [Acute and chronic leukemias. Current aspects of pathogenesis, diagnosis and therapy]. Der Internist. 43: 1177-8. PMID 12524899 DOI: 10.1007/s00108-002-0743-1 |
0.035 |
|
| 2006 |
Buske C, Glimm H, Feuring-Buske M. [Stem cell therapy. Biology of hematopoietic stem cells]. Der Internist. 47: 459-60, 462-4. PMID 16575612 DOI: 10.1007/s00108-006-1602-2 |
0.034 |
|
| 2015 |
Viardot A, Buske C. Indolent lymphomas in older patients Management of Hematological Cancer in Older People. 129-141. DOI: 10.1007/978-1-4471-2837-3_8 |
0.034 |
|
| 2004 |
Buske C, Matheisen J, Zeise M. Ecological site supervision in road construction projects in Thuringia - Options to avoid environmental damage during construction | Anwendung der Umweltbaubegleitung bei Straßenbauvorhaben in Thüringen - Tätigkeiten zur Vermeidung von Umweltschäden in der Baupraxis Naturschutz Und Landschaftsplanung. 36: 14-20. |
0.032 |
|
| 2012 |
Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM, Bohlander SK, Braess J, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Feuring-Buske M, Buske C, et al. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Annals of Hematology. 91: 9-18. PMID 21744003 DOI: 10.1007/s00277-011-1280-6 |
0.032 |
|
| 2006 |
Metzeler K, Fritsch S, Buske C, Hiddemann W. [Acute myeloid leukemia -- on the way towards pathogenesis-oriented treatment]. Deutsche Medizinische Wochenschrift (1946). 131: 1466-8. PMID 16794978 DOI: 10.1055/s-2006-946603 |
0.032 |
|
| 1997 |
Wulf GG, Jürgens B, Liersch T, Gatzemeier W, Rauschecker H, Buske C, Hüfner M, Hiddemann W, Wörmann B. Reverse transcriptase/polymerase chain reaction analysis of parathyroid hormone-related protein for the detection of tumor cell dissemination in the peripheral blood and bone marrow of patients with breast cancer Journal of Cancer Research and Clinical Oncology. 123: 514-521. PMID 9341902 DOI: 10.1007/s004320050097 |
0.032 |
|
| 2005 |
Dreyling M, Buske C, Hiddemann W. [Up-to-date treatment of follicular lymphomas]. Deutsche Medizinische Wochenschrift (1946). 130: 2149-54. PMID 16172957 DOI: 10.1055/s-2005-916357 |
0.031 |
|
| 2007 |
Kohl TM, Hellinger C, Ahmed F, Buske C, Hiddemann W, Bohlander SK, Spiekermann K. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia. 21: 1763-72. PMID 17554384 DOI: 10.1038/sj.leu.2404776 |
0.031 |
|
| 2008 |
Archangelo LF, Greif PA, Hölzel M, Harasim T, Kremmer E, Przemeck GK, Eick D, Deshpande AJ, Buske C, de Angelis MH, Saad ST, Bohlander SK. The CALM and CALM/AF10 interactor CATS is a marker for proliferation. Molecular Oncology. 2: 356-67. PMID 19383357 DOI: 10.1016/j.molonc.2008.08.001 |
0.031 |
|
| 2012 |
Herold T, Seiler T, Egensperger R, Trumm C, Bergmann M, Franke D, Mumm FF, Schinwald N, Buske C, Dreyling M. Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia. Leukemia & Lymphoma. 53: 169-72. PMID 21812535 DOI: 10.3109/10428194.2011.608446 |
0.031 |
|
| 2006 |
Weigert O, Dreyling M, Unterhalt M, Hiddemann W, Buske C. Investigational strategies in autologous stem cell transplantation for follicular lymphoma. Current Oncology Reports. 8: 368-75. PMID 16901398 DOI: 10.1007/s11912-006-0060-2 |
0.031 |
|
| 1978 |
Krell L, Buske C, Elste G, Dinger E. Indirect hemagglutination in diagnosis of gonorrhea | VERSUCHE ZUR ANWENDUNG DER INDIREKTEN HAMAGGLUTINATION BEI DER DIAGNOSTIK DER GONORRHOE Dermatologische Monatsschrift. 164: 361-366. PMID 98361 |
0.029 |
|
| 1999 |
Buske C, Raabe R. Accompanying ecological measures for construction - Options and limitations for the realisation of road construction projects | Okologische Baubegleitung Moglichkeiten und grenzen bei der realisierung von strassenbauprojekten Naturschutz Und Landschaftsplanung. 31: 367-371. |
0.028 |
|
| 2006 |
Fritsch S, Metzeler K, Hiddemann W, Buske C. [Diagnostics and therapy of acute myeloid leukemia]. Deutsche Medizinische Wochenschrift (1946). 131: 2401-6. PMID 17054056 DOI: 10.1055/s-2006-955022 |
0.028 |
|
| 2006 |
Hiddemann W, Spiekermann K, Braess J, Feuring-Buske M, Buske C, Büchner T. [Risk-adapted therapy of acute myeloid leukemia]. Der Internist. 47: S33-9. PMID 16773364 DOI: 10.1007/s00108-006-1622-y |
0.028 |
|
| 2000 |
Buske C, Humphries RK. Homeobox genes in leukemogenesis International Journal of Hematology. 71: 301-308. PMID 10905048 |
0.028 |
|
| 2009 |
Buske C, Richter C, Thiele FH, Yu C, Zhuang M. Validation of a zonal method computing the sound radiation from lined ducts 15th Aiaa/Ceas Aeroacoustics Conference (30th Aiaa Aeroacoustics Conference). |
0.028 |
|
| 1997 |
Buske C, Hannig H, Hiddemann W, Bodemer W. Human herpesvirus-8 (HHV-8) DNA associated with anaplastic large cell lymphoma of the B-cell type in an HIV-1-positive patient International Journal of Cancer. Journal International Du Cancer. 73: 303-304. PMID 9335459 |
0.027 |
|
| 2006 |
Buske C, Weigert O, Dreyling M, Unterhalt M, Hiddemann W. Current status and perspective of antibody therapy in follicular lymphoma. Haematologica. 91: 104-12. PMID 16434378 |
0.026 |
|
| 2009 |
Deshpande A, Pastore A, Deshpande AJ, Zimmermann Y, Hutter G, Weinkauf M, Buske C, Hiddemann W, Dreyling M. 3′UTR mediated regulation of the cyclin D1 proto-oncogene Cell Cycle. 8: 3592-3600. |
0.026 |
|
| 2011 |
Azimzadeh O, Scherthan H, Sarioglu H, Barjaktarovic Z, Conrad M, Vogt A, Calzada-Wack J, Neff F, Aubele M, Buske C, Atkinson MJ, Tapio S. Rapid proteomic remodeling of cardiac tissue caused by total body ionizing radiation. Proteomics. 11: 3299-311. PMID 21751382 DOI: 10.1002/pmic.201100178 |
0.026 |
|
| 2009 |
Deshpande A, Pastore A, Deshpande AJ, Zimmermann Y, Hutter G, Weinkauf M, Buske C, Hiddemann W, Dreyling M. 3'UTR mediated regulation of the cyclin D1 proto-oncogene. Cell Cycle (Georgetown, Tex.). 8: 3592-600. PMID 19823025 |
0.026 |
|
| 2015 |
Buske C, Seymour JF. Immunochemotherapy in Waldenström macroglobulinemia - still the backbone of treatment. Leukemia & Lymphoma. 56: 2489-90. PMID 26054374 DOI: 10.3109/10428194.2015.1058938 |
0.026 |
|
| 2011 |
Buske C, Dreyling M. Indolent non-Hodgkin's lymphomas | Übersicht - Indolente Non-Hodgkin-Lymphome Tumor Diagnostik Und Therapie. 32: 23-25. DOI: 10.1055/s-0031-1273286 |
0.026 |
|
| 1998 |
Buske C, Becker D, Feuring-Buske M, Hannig H, Griesinger F, Hiddemann W, Wormann B. TGF-β and its receptor complex in leukemic B-cell precursors Experimental Hematology. 26: 1155-1161. PMID 9808055 |
0.025 |
|
| 1996 |
Wulf GG, Jahns-Streubel G, Strutz F, Basenau D, Hüfner M, Buske C, Wörmann B, Hiddemann W. Paraneoplastic hypokalemia in acute myeloid leukemia: A case of renin activity in AML blast cells Annals of Hematology. 73: 139-141. PMID 8841102 DOI: 10.1007/s002770050215 |
0.025 |
|
| 2011 |
Kuchenbauer F, Mah SM, Heuser M, McPherson A, Rüschmann J, Rouhi A, Berg T, Bullinger L, Argiropoulos B, Morin RD, Lai D, Starczynowski DT, Karsan A, Eaves CJ, Watahiki A, ... ... Buske C, et al. Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood. 118: 3350-8. PMID 21628414 DOI: 10.1182/Blood-2010-10-312454 |
0.025 |
|
| 2010 |
Buske C, Richter C, Thiele F, Yu C, Zhuang M. Validation of a zonal approach computing the sound radiation from lined ducts Aiaa Journal. 48: 2899-2908. DOI: 10.2514/1.J050478 |
0.024 |
|
| 2012 |
Azimzadeh O, Scherthan H, Yentrapalli R, Barjaktarovic Z, Ueffing M, Conrad M, Neff F, Calzada-Wack J, Aubele M, Buske C, Atkinson MJ, Hauck SM, Tapio S. Label-free protein profiling of formalin-fixed paraffin-embedded (FFPE) heart tissue reveals immediate mitochondrial impairment after ionising radiation. Journal of Proteomics. 75: 2384-95. PMID 22387116 DOI: 10.1016/j.jprot.2012.02.019 |
0.024 |
|
| 1997 |
Buske C, Sack H, Hiddemann W. Follicular germinal center lymphomas: Current state of therapy | Follikulare Keimzentrumslymphome. Aktueller Stand in der Therapie Onkologe. 3: 504-512. DOI: 10.1007/s007610050148 |
0.024 |
|
| 2007 |
Fritsch S, Buske C, Wörmann B, Wedding U, Hiddemann W, Spiekermann K. [Therapy of acute myeloid leukemia (AML) for medically non-fit patients]. Medizinische Klinik (Munich, Germany : 1983). 102: 324-9. PMID 17426936 DOI: 10.1007/s00063-007-1038-z |
0.024 |
|
| 2012 |
Langer C, Rücker FG, Buske C, Döhner H, Kuchenbauer F. Targeted therapies through microRNAs: pulp or fiction? Therapeutic Advances in Hematology. 3: 97-104. PMID 23556116 DOI: 10.1177/2040620711432582 |
0.023 |
|
| 2013 |
Adamczuk RR, Buske C, Roehle I, Hennecke C, Dinkelacker F, Seume JR. Impact of defects and damage in aircraft engines on the exhaust jet Proceedings of the Asme Turbo Expo. 2. DOI: 10.1115/GT2013-95079 |
0.022 |
|
| 2012 |
Mulaw MA, Krause A, Krause AJ, Deshpande AJ, Krause LF, Rouhi A, La Starza R, Borkhardt A, Buske C, Mecucci C, Ludwig WD, Lottaz C, Bohlander SK. CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12. Leukemia. 26: 1012-9. PMID 22064352 DOI: 10.1038/leu.2011.307 |
0.022 |
|
| 2007 |
Heilmeier B, Buske C, Spiekermann K, Bohlander S, Feuring-Buske M, Hiddemann W, Braess J. [Diagnostics, classification and prognostic criteria of acute myeloid leukemia]. Medizinische Klinik (Munich, Germany : 1983). 102: 296-308. PMID 17426933 DOI: 10.1007/s00063-007-1036-1 |
0.022 |
|
| 2007 |
Schmitz N, Buske C, Gisselbrecht C. Autologous stem cell transplantation in lymphoma. Seminars in Hematology. 44: 234-45. PMID 17961722 DOI: 10.1053/j.seminhematol.2007.08.007 |
0.022 |
|
| 2005 |
Kuchenbauer F, Feuring-Buske M, Buske C. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia. Cell Cycle (Georgetown, Tex.). 4: 1716-8. PMID 16294039 |
0.022 |
|
| 2013 |
Buske C, Ullrich WC, Roehle I. Numerical study of incidence angles and gap heights in turbine cascades and rotors on tip clearance losses Proceedings of the Asme Turbo Expo. 6. DOI: 10.1115/GT2013-94872 |
0.021 |
|
| 2007 |
Buske C, Unterhalt M, Hiddeman W. [Therapy of follicular lymphoma]. Der Internist. 48: 372-81. PMID 17287964 DOI: 10.1007/s00108-007-1804-2 |
0.021 |
|
| 2004 |
Buske C, Dreyling M, Unterhalt M, Hiddemann W. [Monoclonal antibody treatment of malignant lymphoma]. Der Internist. 45: 1370-7. PMID 15517123 DOI: 10.1007/s00108-004-1299-z |
0.021 |
|
| 1997 |
Buske C, Becker D, Feuring-Buske M, Hannig H, Wulf G, Schäfer C, Hiddemann W, Wörmann B. TGF-β inhibits growth and induces apoptosis in leukemic B cell precursors Leukemia. 11: 386-392. PMID 9067578 |
0.021 |
|
| 2005 |
Hiddemann W, Spiekermann K, Buske C, Feuring-Buske M, Braess J, Haferlach T, Schoch C, Kern W, Schnittger S, Berdel W, Wörmann B, Heinecke A, Sauerland C, Büchner T. Towards a pathogenesis-oriented therapy of acute myeloid leukemia. Critical Reviews in Oncology/Hematology. 56: 235-45. PMID 16207531 DOI: 10.1016/j.critrevonc.2005.07.004 |
0.02 |
|
| 2007 |
Buske C, Hiddemann W. [The older patient with malignant diseases]. Der Internist. 48: 1206,1208-10. PMID 17934703 DOI: 10.1007/s00108-007-1955-1 |
0.02 |
|
| 2005 |
Buske C, Dreyling M, Unterhalt M, Hiddemann W. Transplantation strategies for patients with follicular lymphoma. Current Opinion in Hematology. 12: 266-72. PMID 15928482 DOI: 10.1097/01.moh.0000166499.72138.57 |
0.02 |
|
| 2004 |
Buske C. Plasma activation of EPDM and TPE profiles - Plasma replaces mechanical brushing or priming Flock. 30: 21-24. |
0.02 |
|
| 2014 |
Buske C. Towards a chemotherapy-free approach in indolent lymphoma. The Lancet. Oncology. 15: 1281-2. PMID 25439681 DOI: 10.1016/S1470-2045(14)70488-7 |
0.019 |
|
| 1998 |
Buske C, Engert A, Schnell R, Diehl V, Hiddemann W. Monoclonal antibodies in the therapy of malignant lymphoma | Monoklonale antikorper in der therapie maligner lymphome Internist. 39: 1205-1214. PMID 10198827 DOI: 10.1007/s001080050292 |
0.019 |
|
| 2007 |
Christ O, Feuring-Buske M, Hiddemann W, Buske C. [Pathobiology of acute myeloid leukemia]. Medizinische Klinik (Munich, Germany : 1983). 102: 290-5. PMID 17426932 DOI: 10.1007/s00063-007-1035-2 |
0.018 |
|
| 2007 |
Buske C, Hiddemann W. [Malignant lymphoma--there are still many open questions]. Der Internist. 48: 349-50. PMID 17361404 DOI: 10.1007/s00108-007-1836-7 |
0.018 |
|
| 2005 |
Buske C, Knospe A. In-line plasma process | Plasmaprozesse in-line Kunststoffe Plast Europe. 95: 82-86. |
0.018 |
|
| 2005 |
Buske C, Dreyling M, Unterhalt M, Hiddemann W. [Monoclonal antibody therapy for malignant lymphoma]. Medizinische Klinik (Munich, Germany : 1983). 100: 14-24. PMID 15654538 DOI: 10.1007/s00063-005-1115-0 |
0.018 |
|
| 2015 |
Schneider D, Dühren-von Minden M, Alkhatib A, Setz C, van Bergen CA, Benkißer-Petersen M, Wilhelm I, Villringer S, Krysov S, Packham G, Zirlik K, Römer W, Buske C, Stevenson FK, Veelken H, et al. Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma. Blood. 125: 3287-96. PMID 25784678 DOI: 10.1182/blood-2014-11-609404 |
0.017 |
|
| 1999 |
Buske C, Hannig H, Schneider EM, Blaschke S, Hunsmann G, Bodemer W, Hiddemann W. Transforming growth factor β is a growth-inhibitory cytokine of B cell lymphoma in SIV-infected macaques Aids Research and Human Retroviruses. 15: 1477-1485. PMID 10555111 DOI: 10.1089/088922299309991 |
0.017 |
|
| 1997 |
Buske C, Twiling A, Gogowski G, Schreiber K, Feuring-Buske M, Wulf GG, Hiddemann W, Wörmann B. In vitro activation of low-grade non-Hodgkin's lymphoma by murine fibroblasts, IL-4, anti-CD40 antibodies and the soluble CD40 ligand. Leukemia. 11: 1862-7. PMID 9369419 |
0.016 |
|
| 2011 |
Herold T, Jurinovic V, Mulaw M, Seiler T, Dufour A, Schneider S, Kakadia PM, Feuring-Buske M, Braess J, Spiekermann K, Mansmann U, Hiddemann W, Buske C, Bohlander SK. Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20. Genes, Chromosomes & Cancer. 50: 546-58. PMID 21500311 DOI: 10.1002/gcc.20879 |
0.015 |
|
| 2001 |
Blaschke S, Hannig H, Buske C, Kaup FJ, Hunsmann G, Bodemer W. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques. Journal of Medical Virology. 65: 114-20. PMID 11505452 DOI: 10.1002/jmv.2009 |
0.014 |
|
| 2010 |
Mah SM, Buske C, Humphries RK, Kuchenbauer F. miRNA*: a passenger stranded in RNA-induced silencing complex? Critical Reviews in Eukaryotic Gene Expression. 20: 141-8. PMID 21133843 |
0.014 |
|
| 2007 |
Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Unterhalt M. Current management of follicular lymphomas. British Journal of Haematology. 136: 191-202. PMID 17073892 DOI: 10.1111/j.1365-2141.2006.06378.x |
0.013 |
|
| 2012 |
Grasedieck S, Schöler N, Bommer M, Niess JH, Tumani H, Rouhi A, Bloehdorn J, Liebisch P, Mertens D, Döhner H, Buske C, Langer C, Kuchenbauer F. Impact of serum storage conditions on microRNA stability. Leukemia. 26: 2414-6. PMID 22504138 DOI: 10.1038/leu.2012.106 |
0.012 |
|
| 1997 |
Buske C, Gogowski G, Schreiber K, Rave-Fränk M, Hiddemann W, Wörmann B. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand. Experimental Hematology. 25: 329-37. PMID 9131008 |
0.012 |
|
| 2013 |
Grishin A, Knospe A, Buske C. Application of PlasmaPlus® plasma coating technology for hybrid polymer-metal components in the automotive industry Society of Plastics Engineers - Eurotech 2013. 187-192. |
0.011 |
|
| 2013 |
Buske C, Leblond V. How to manage Waldenstrom's macroglobulinemia. Leukemia. 27: 762-72. PMID 23385376 DOI: 10.1038/leu.2013.36 |
0.01 |
|
| 2010 |
Buske C. Hematologic malignancies-sixth European congress. 26-28 February 2010, Cannes, France . Idrugs : the Investigational Drugs Journal. 13: 300-3. PMID 20432183 |
0.01 |
|
| 2006 |
Schüssler J, Buske C. Atmospheric in-line plasma in medical technology | Atmosphärisches in-line-plasma in der medizintechnik Kunststoffe International. 96: 72-74. |
0.01 |
|
| 2006 |
Buske C, Schüssler J. Definitely "not superficial" | Durchaus "nicht oberflächlich" Adhaesion Kleben Und Dichten. 16-19. |
0.01 |
|
| Hide low-probability matches. |